In a syngeneic mouse tumor model and patients receiving anti-PD-1/PD-L1 therapy, tumors expressing a high level of tyrosine-protein kinase receptor (Tyro3) present resistance to anti-PD-1/PD-L1 therapy by inhibiting ferroptosis (Jiang Z. et al., 2021). This evidence concerns the gene TYRO3 and neoplasm.